Finanzen von SpyGlass Pharma Inc (SGP)SGPSpyGlass Pharma Inc

In the context of the broader market, SGP competes directly with industry leaders such as KURA and VSTM. With a market capitalization of $926.84M, it holds a significant position in the sector. When comparing efficiency, SGP's gross margin of N/A stands against KURA's 98.84% and VSTM's 89.92%. Such benchmarking helps identify whether SpyGlass Pharma, Inc. is trading at a premium or discount relative to its financial performance.

SpyGlass Pharma has reported a widening net loss of $19.9 million for Q2 2026, up from $8.7 million in the same quarter last year. The company's EPS for Q2 2026 was -0.59, which is worse than the estimated -0.48. This indicates deteriorating financial health despite some potential for future growth in drug development.